The overlap of all three treatments appears to be a reduction in eosinophilia, also observed with bisdionin F. Approaches that more specifically targeted AMCase yielded additional effects not seen with broad chitinase inhibitors, including reduction of IL-13-induced chemotactic factors, antigen-specific IgE responses, and airway hyperresponsiveness. The gene discussed is IGHE; the disease is Increased total eosinophil count.